Cisatracurium IV

Cisatracurium IV is a non‑depolarizing neuromuscular blocker used to produce skeletal muscle relaxation for intubation and ventilation support.

mgmcg
mlL
kglb
mg/kg/minmg/kg/hrmcg/kg/minmcg/kg/hr

Indications for Use

Used for neuromuscular blockade to facilitate endotracheal intubation, optimize surgical conditions, and ensure ventilator synchrony in ICU patients, including early severe ARDS where cisatracurium was the NMBA in major RCTs 1 [Level I evidence]. Also preferred in hepatic impairment because elimination is organ‑independent 2 [Level II evidence]. Clinical utility: predictable kinetics, low histamine release, and stable hemodynamics.

Insights & Cautions

Avoid prolonged wording. (≈70 words)

Use cisatracurium for predictable, organ‑independent (Hoffmann) metabolism; stable in renal/hepatic impairment and low hemodynamic effect. Major cautions: anaphylaxis risk (rare but documented in pharmacovigilance surveys 1 [Level II evidence]), residual neuromuscular block without quantitative monitoring 2 [Level II evidence], and exaggerated effect in myasthenia gravis. Not suitable for RSI.

Cisatracurium is a non‑depolarizing NMBA with 2–3‑min onset and ~60‑min duration (ASHP Drug Compendium [Cisatracurium; Neuromuscular Blckrs]).